Analytical Data
-
基因名
HLA-A*24:02&B2M&MAGE-A3(IMPKAGLLI) Monomer
- Application
-
别名
MAGE family member A3; HIP8; HYPD; CT1.3; MAGE3; MAGEA6
-
种属
Human
-
表达系统
HEK293
-
标签
C-Avi;C-8*His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
AAA59600.1 (G25-T305)&P61769
-
表达区间
AAA59600.1 (G25-T305)&P61769 (I21-M119)&IMPKAGLLI
-
分子量
55-60 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The study of HLA-A*24:02, B2M, and MAGE-A3 (IMPKAGLLI) monomer recombinant protein is rooted in the field of immunology and cancer research. HLA-A*24:02 is a prevalent human leukocyte antigen (HLA) allele linked to various diseases and is of particular interest due to its role in presenting tumor-associated antigens to T cells. MAGE-A3, a well-characterized cancer/testis antigen, is expressed in several tumors but not in normal tissues, making it an attractive target for immunotherapy. The peptide IMPKAGLLI, derived from MAGE-A3, has been identified as an important epitope that can elicit a robust immune response. In tandem with β2-microglobulin (B2M), which stabilizes the HLA class I molecules on cell surfaces, the recombinant expression of these proteins facilitates the investigation of their interactions and functionality. This research aims to advance our understanding of antigen presentation and immune evasion in cancer, ultimately contributing to the development of targeted immunotherapeutic strategies. By studying the HLA-A*24:02/B2M/MAGE-A3 complex, researchers can explore its potential in vaccine development and personalized medicine approaches for patients with cancers expressing MAGE-A3. This could lead to enhanced T-cell responses and improved clinical outcomes in immunotherapy.
